glp-1 usage statistics The Evolution of Users GLP-1 Antagonists Increase Plan Drug

For patients, this means navigating a more complex treatment landscape, where outcomes depend not only on the drug itself but on the system surrounding it

Eli Lilly plans to submit for the type 2 diabetes indication in 2026

As expected, members who took the medication for increasingly longer periods of time and at increasingly greater doses (according to standard medication titration prescription recommendations) experienced greater weight loss

[DOI] [PMC free article] [PubMed] [Google Scholar] 96.Sivasankaran RP, et al

examined 19 clinical trials that investigated the use of exenatide, semaglutide, and liraglutide as pharmacologic options for treating childhood obesity alongside behavioral and lifestyle interventions, as well as surgical approaches